18. June 2015

New website launched



Visit our new website!

•    Improved usability on your desktop device.
•    Easy and fast access to our products.
•    Information on latest product developments, news and events.
•    Blog on current research insights and trends in the transglutaminase field!

_________________________________________________________________________________

Labeled proteins required? Do it yourself using our TGase Protein Labeling Kits:
Art. No.   Name Unit Price
L001 Substrate Finder Kit 1 Kit     310 €
L101 Biotin TGase Protein Q-Labeling Kit
(sufficient for 5 x 1 mg labeling reactions)           
1 Kit          520 €
L201 Biotin TGase Protein K-Labeling Kit
(sufficient for 5 x 1 mg labeling reactions)
1 Kit  520 €

Further, kits for Glutamine (Q)- or Lysine (K)-labeling with the following labels are available:
PEG1,088, PEG5,000, ATTO-488TM, ATTO-532TM, ATTO-550TM, ATTO-647NTM, and ATTO-700TM.

Please contact us if other labels are required: contact@zedira.com

Document

Products

  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.

News  

  • Press release: Dr. Falk Pharma and Zedira announce start of the phase 2a proof of concept study of ZED1227 for the treatment of celiac disease
  • Artikel in DLG-Lebensmittel – 06/2017 zur Bestimmung von Transglutaminase in Lebensmitteln (deutsch)
  • Zedira publication: Microbial Transglutaminase Used in Bread Preparation at Standard Bakery Concentrations Does Not Increase Immunodetectable Amounts of Deamidated Gliadin
  • Pressemitteilung: Dr. Falk Pharma und Zedira geben den Abschluss der Phase 1b-Studie für ZED1227 zur Zöliakie-Therapie bekannt und planen Start der Wirksamkeitsstudie
  • Press release: Dr. Falk Pharma and Zedira announce completion of phase 1b clinical trial of ZED1227 for the treatment of celiac disease and move on to proof of concept study
  • Press Release: Dr. Falk Pharma GmbH and Zedira enter a phase 1b clinical trial for a celiac disease drug
  • Zedira publication: Microbial transglutaminase has a lower deamidation preference than human tissue transglutaminase on a celiac disease relevant wheat gliadin T-cell epitope
  • Press release: Additional subsidy funding for clinical development of a celiac disease drug
  • Pressemitteilung: Zusätzliche Fördermittel für die klinische Entwicklung eines Zöliakie-Medikamentes
  • Press Release: Cooperation between Zedira and Cardiff University - Transglutaminase 6 is the focus of new research into ataxia
  • Press Release: Dr. Falk Pharma and Zedira enter phase I clinical trials for a celiac disease drug
  • Press release: Zedira receives further funding to develop Factor XIIIa-blockers for safe anticoagulation

Blog  

Events  

  • Life Sciences 2019: Post-translational modifications and cell signalling

    17.03.2019 - 18.03.2019
    Nottingham, UK

  • 10th International meeting of the Society for research on the Cerebellum and Ataxias (SRCA)

    16.05.2019 - 17.05.2019
    Sheffield, UK

  • 18th International Celiac Disease Symposium ICDS

    04.09.2019 - 07.09.2019
    Paris, France